Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,604.50
Bid: 1,604.00
Ask: 1,604.50
Change: -5.50 (-0.34%)
Spread: 0.50 (0.031%)
Open: 1,611.50
High: 1,615.50
Low: 1,599.50
Prev. Close: 1,610.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GSK Annual Report 2023 on Form 20-F

5 Mar 2024 17:24

RNS Number : 7075F
GSK PLC
05 March 2024
 

Issued: 5 March 2024, London UK

 

GSK plc 2023 Annual Report on Form 20-F

 

 

In accordance with Section 203.01 of the New York Stock Exchange Listed Company Manual, GSK plc ("GSK") announces that on 5 March 2024 it filed with the Securities and Exchange Commission an Annual Report on Form 20-F that included audited financial statements for the year ended 31 December 2023. GSK's 2023 Annual Report on Form 20-F is available online at GSK's website at www.gsk.com/corporatereporting and also online at www.sec.gov.

A hard copy version of the GSK 2023 Annual Report, together with the Notice of Annual General Meeting, will be available on or about 25 March 2024.

Shareholders have the ability to receive, upon request, a hard copy version of GSK's complete audited financial statements for the year ended 31 December 2023, free of charge, by either:

 

(i)

writing to Equiniti Limited, our registrars in the UK, at the following address: Equiniti Limited, Aspect House, Spencer Road, Lancing, West Sussex BN99 6DA, or by telephone on +44 (0)371 384 2991 (please use the area code if calling from outside the UK);

 

(ii)

writing to J.P. Morgan Chase Bank, N.A. our ADR depositary in the US, at the following address: EQ Shareowner Services, P.O. Box 64504, St. Paul, MN 55164-0504, or by telephone on +1 877 353 1154 (US toll free) or +1 651 453 2128 (outside the US); or

 

(iii)

contacting the GSK Response Center in the USA at +1 888 825 5249 (US toll free).

 

 

 

About GSK GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

 

Victoria WhyteCompany Secretary5 March 2024

 

Cautionary statement regarding forward-looking statements GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors" in the company's Annual Report on Form 20-F for 2023.

 

Registered in England & Wales:

No. 3888792

 

Registered Office:

980 Great West Road

Brentford, Middlesex

TW8 9GS

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSQKPBBOBKDKNK
Date   Source Headline
14th Jan 20204:01 pmRNSDirector/PDMR Shareholding
13th Jan 20206:00 pmRNSDirector/PDMR Shareholding
13th Jan 202011:41 amRNSDirector/PDMR Shareholding
13th Jan 202011:01 amRNSDirector/PDMR Shareholding
13th Jan 202010:34 amRNSDirector/PDMR Shareholding
8th Jan 20204:30 pmRNSGSK publishes provisional 2020 Dividend Dates
8th Jan 20203:11 pmRNSGSK publishes 2020 Dividend Dates
8th Jan 20202:37 pmRNSGSK Announces addition to Corporate Executive Team
2nd Jan 20209:58 amRNSTotal Voting Rights
23rd Dec 20197:01 amRNSViiV Healthcare receives complete response letter
18th Dec 20195:12 pmRNSDirector/PDMR Shareholding
18th Dec 20194:55 pmRNSDirector/PDMR Shareholding
17th Dec 20199:00 amRNSBlocklisting Application
13th Dec 20194:48 pmRNSDirector/PDMR Shareholding
11th Dec 20194:57 pmRNSDirector/PDMR Shareholding
5th Dec 201912:00 pmRNSViiV submits NDA to FDA for fostemsavir
4th Dec 20195:34 pmRNSEmma Walmsley - External Appointment
2nd Dec 20195:52 pmRNSDirector/PDMR Shareholding
2nd Dec 20194:54 pmRNSTotal Voting Rights
26th Nov 20193:00 pmRNSBlock listing Interim Review
12th Nov 20193:51 pmRNSDirector/PDMR Shareholding
8th Nov 20194:22 pmRNSDirector/PDMR Shareholding
6th Nov 20194:36 pmRNSDirector/PDMR Shareholding
4th Nov 20195:35 pmRNSDirector/PDMR Shareholding
1st Nov 20195:19 pmRNSDirector/PDMR Shareholding
1st Nov 20199:53 amRNSTotal Voting Rights
31st Oct 20191:34 pmRNSDirector/PDMR Shareholding
30th Oct 20195:32 pmRNSDirector/PDMR Shareholding
30th Oct 201912:07 pmRNSSecond Price Monitoring Extn
30th Oct 201912:02 pmRNSPrice Monitoring Extension
30th Oct 201912:00 pmRNS3rd Quarter Results
21st Oct 20198:00 amRNSGSK divests two travel vaccines to Bavarian Nordic
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
15th Oct 20195:00 pmRNSDirector/PDMR Shareholding
11th Oct 20195:34 pmRNSDirector/PDMR Shareholding
11th Oct 20194:10 pmRNSDirector/PDMR Shareholding
10th Oct 20194:18 pmRNSDirector/PDMR Shareholding
1st Oct 20196:18 pmRNSDirector/PDMR Shareholding
1st Oct 20191:09 pmRNSTotal Voting Rights
30th Sep 20197:00 amRNSPRIMA shows Zejula improves PFS in ovarian cancer
30th Sep 20197:00 amRNSData show anti-tumour activity with ICOS agonist
26th Sep 20196:26 pmRNSDirector/PDMR Shareholding
17th Sep 20195:46 pmRNSDirector/PDMR Shareholding
11th Sep 20194:30 pmRNSDirector/PDMR Shareholding
4th Sep 20195:37 pmRNSDirector/PDMR Shareholding
4th Sep 201912:36 pmRNSDirector/PDMR Shareholding
4th Sep 20199:33 amRNSDirector/PDMR Shareholding
2nd Sep 201911:29 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.